as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,495.4
Change
-10.8 (-0.72%)
Open
₹1,506.0
Prev. Close
₹1,506.2
Day High
₹1,509.7
Day Low
₹1,479.9
Volume Analysis
Traded
158,143
Delivered
82,399
Delivery %
52.1%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (21.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (19.4%)
- •Strong 3-year revenue growth (17.6%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,539.9 | ₹1,524.8 | ₹1,510.1 | ₹1,495.0 | ₹1,480.3 | ₹1,465.2 | ₹1,450.5 |
| Fibonacci | ₹1,524.8 | ₹1,513.42 | ₹1,506.38 | ₹1,495.0 | ₹1,483.62 | ₹1,476.58 | ₹1,465.2 |
| Camarilla | ₹1,503.6 | ₹1,500.86 | ₹1,498.13 | ₹1,495.0 | ₹1,492.67 | ₹1,489.94 | ₹1,487.21 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+25.46%
1 Week
-0.84%
1 Month
+1.58%
3 Months
+13.82%
6 Months
+51.17%
1 Year
+15.06%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹261.66
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.18%
Net margin 11.79% × asset turnover 0.75x × equity multiplier 1.49x
Company Overview
Sector
Healthcare
Market Cap
₹40,516 Cr
P/E (TTM)
70.8
ROE
15.2%
Book Value
₹147.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Global Health Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 80.7% CAGR over last 5 years
- −Stock is trading at 10.2 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Management to meet Arohi Asset Management on September 25, 2026 via virtual one-on-one meeting.
Intimation under Regulation 30 of Listing Regulations regarding allotment of shares.
Global Health will meet USS Investment Management Ltd on September 23, 2026 in Gurugram.
22nd AGM voting results declared; final dividend of ₹0.50 per share approved on September 16, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Expenses + | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 |
| Operating Profit | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 |
| OPM % | 24.0% | 25.0% | 26.0% | 22.0% | 22.0% | 24.0% | 25.0% | 24.0% | 24.0% | 21.0% | 19.0% | 21.0% | 22.0% |
| Other Income + | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 |
| Interest | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 |
| Depreciation | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 |
| Profit before tax | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Tax % | 28.0% | 27.0% | 28.0% | 11.0% | 26.0% | 28.0% | 24.0% | 24.0% | 24.0% | 21.0% | 21.0% | 24.0% | 26.0% |
| Net Profit + | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS in Rs | 4 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 6 | 6 | 4 | 5 | 6 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 | 4,683 |
| Expenses + | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,480 | 3,705 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 930 | 979 |
| OPM % | 22.0% | 9.0% | 12.0% | 13.0% | 14.0% | 21.0% | 24.0% | 25.0% | 24.0% | 21.0% | 21.0% |
| Other Income + | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 | 80 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 90 | 92 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 246 |
| Profit before tax | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 720 |
| Tax % | 35.0% | 45.0% | 38.0% | 43.0% | 11.0% | 30.0% | 27.0% | 24.0% | 26.0% | 23.0% | — |
| Net Profit + | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 552 |
| EPS in Rs | 35 | 7 | 10 | 7 | 6 | 8 | 12 | 18 | 18 | 21 | 21 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 |
| Borrowings + | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 |
| Other Liabilities + | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
| Fixed Assets + | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets + | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Cash from Investing Activity + | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Cash from Financing Activity + | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| CFO/OP | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 90 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -123 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.06% | 0.06% | 0.06% | 0.08% | 0.09% |
| Public | 45.31% | 44.45% | 44.6% | 43.44% | 43.64% | 43.98% | 43.28% | 43.19% | 42.56% | 42.41% | 42.01% | 40.55% |
| Promoters | 33.06% | 33.05% | 33.04% | 33.04% | 33.04% | 33.03% | 33.03% | 33.01% | 33.01% | 33.01% | 33.01% | 33.0% |
| FII | 10.69% | 11.36% | 12.1% | 12.94% | 12.21% | 12.48% | 11.76% | 11.54% | 11.41% | 10.54% | 10.15% | 9.46% |
| DII | 10.93% | 11.15% | 10.25% | 10.57% | 11.11% | 10.51% | 11.93% | 12.2% | 12.97% | 13.99% | 14.76% | 16.89% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Global Health Limited (this stock) | 40,516 | 70.8 | 10.24 | 15.2% |
| Narayana Hrudayalaya Ltd. | 38,040 | 44.1 | 8.38 | 20.5% |
| Emcure Pharmaceuticals L | 37,595 | 36.5 | 7.59 | 20.1% |
| Wockhardt Limited | 36,814 | 92.3 | 7.45 | 6.11% |
| Ajanta Pharma Limited | 44,229 | 39.0 | 9.78 | 27.1% |
| Sai Life Sciences Limited | 33,821 | 92.0 | 13.61 | 15.4% |
| Gland Pharma Limited | 47,846 | 41.8 | 4.61 | 10.7% |
Which Mutual Funds Hold Global Health Limited?
Frequently Asked Questions about Global Health Limited
Global Health Limited (MEDANTA) closed at ₹1,495.4 on NSE on 25 September 2026, down 10.8 (0.72%) from the previous close.
Global Health Limited trades on the NSE (National Stock Exchange of India) under the symbol MEDANTA.
Global Health Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 70.8.
Global Health Limited has a dividend yield of 0.03%.
Global Health Limited's 52-week high is ₹1,544.0 and its 52-week low is ₹955.0.
Global Health Limited has a market capitalisation of ₹40,516 crore.
Global Health Limited has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Global Health Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.